Leishmaniasis: new approaches to disease controlBMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7385.377 (Published 15 February 2003) Cite this as: BMJ 2003;326:377
- Clive R Davies (), head of disease control and vector biology unita,
- Paul Kaye, professor of cellular immunologya,
- Simon L Croft, reader in parasitologya,
- Shyam Sundar, head of departmentb
- a Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT,
- b Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi - 221 005, India
- Correspondence to: C R Davies
The leishmaniases afflict the world's poorest populations. Among the two million new cases each year in the 88 countries where the disease is endemic (fig 1), it is estimated that 80% earn less than $2 a day. Human infections with Leishmania protozoan parasites, transmitted via the bite of a sandfly, cause visceral, cutaneous, or mucocutaneous leishmaniasis. The global burden of leishmaniasis has remained stable for some years, causing 2.4 million disability adjusted life years (DALYs) lost and 59 000 deaths in 2001.1 Neglected by researchers and funding agencies, leishmaniasis control strategies have varied little for decades, but in recent years there have been exciting advances in diagnosis, treatment, and prevention. These include an immunochromatographic dipstick for diagnosing visceral leishmaniasis; the licensing of miltefosine, the first oral drug for visceral leishmaniasis; and evidence that the incidence of zoonotic visceral leishmaniasis in children can be reduced by providing dogs with deltamethrin collars. There is also hope that the first leishmaniasis vaccine will become available within a decade. Here we review these developments and identify priorities for research.
Simple and rapid diagnostic tools for leishmaniasis will soon be widely available
A new range of affordable and effective treatments, including oral drugs, are coming on line
The development of drug resistance is a major concern and needs strategic plans
New methods of applying insecticides for preventing leishmaniasis are likely to take the place of house spraying and (for zoonotic visceral leishmaniasis) dog culling
Strategies need to be developed to optimise progression of vaccine candidates to phase I trials
Current research effort and resources should prioritise visceral leishmaniasis in the Sudan and Indian subcontinent, where the burden of leishmaniasis is greatest
Box 1: Current research priorities for diagnosing leishmaniasis
Develop affordable tools for use in the field (including antigen detection tests) for rapid diagnosis customised for specific geographical regions
Develop semiquantitative rapid methods for prognosis and early detection of relapse
Develop probes for detection of infections with drug resistant strains
This review is based on our personal knowledge of the subject combined with a literature search on the Entrez-PubMed site.
The gold standard for diagnosing visceral leishmaniasis is parasite identification in tissue smears, with splenic aspirate being more sensitive than bone marrow or lymph node aspirates. However, difficulties in obtaining and examining tissues mean that serological methods are increasingly being used.
The direct agglutination test, in which stained parasites are agglutinated by serum antibodies, is popular in Iran and Africa,w1 but variation between batches and the high cost of commercially available antigen are limiting factors. In the Indian subcontinent,2 but less so in Europe and Africa,3w2 a rapid strip test is used to detect antibody to rK39 (a conserved antigen of L infantum) and is both sensitive (67-100%) and specific (93-100%) (fig 2). Weak responses in some patients, persistence of antibodies after cure, and presence of antibodies in some healthy individuals are inherent limitations with antibody based diagnostics.
Detection of leishmanial antigen in urine through a latex agglutination test (Katex) seems to be promising for both diagnosis and prognosis.4 Techniques based on polymerase chain reaction are potentially highly sensitive and specific,5 but they need to be made more suitable for field use in terms of cost and user skills required. In patients co-infected with HIV and visceral leishmaniasis, blood smears and culture might yield good results.w3
Cutaneous and mucocutaneous leishmaniasis
Touch smears or culture of exudates or scrapings yield good results in the diagnosis of cutaneous leishmaniasis. From a nodule, slit skin smears are often rewarding. Tissue biopsy can be used for impression smears, culture, or animal inoculation, especially for mucocutaneous leishmaniasis. Although multiple Leishmania species sometimes coexist, species identification is unlikely to be cost effective in the field unless major treatment decisions for cutaneous leishmaniasis become species specific.
For six decades, long parenteral courses of pentavalent antimonial (Sbv) drugs have been used for both visceral and cutaneous leishmaniasis. The second line drugs amphotericin and the less frequently used pentamidine isetionate are toxic. The difficulties of treatment are exacerbated by the spread of resistance to antimony in India6 and the intractability of the disease to all drugs in patients co-infected with HIV.w3 In most endemic countries the use of some excellent treatments, notably liposomal amphotericin (AmBisome) for visceral leishmaniasis, is limited by patients' inability to pay.7
Box 2: Topical paromomycin formulations for cutaneous leishmaniasis
In placebo controlled trials 15% paromomycin+12% methylbenzethonium chloride ointment gave cure rates of 74% in Europe, Asia, and Africaw10 and 85% in North and South Americaw11
15% paromomycin+0.5% gentamicin+10 surfactant vehicle gave cure in 35 days compared with 56 days for placebow12
Concerns about treatment failure for visceral leishmaniasis are exacerbated by geographical variations in antimonial treatment regimens, severity of disease, and sensitivity of Leishmania species. In north Bihar (India) there is clear evidence of acquired resistance of L donovani to antimonials,w4 with up to 60% failure rate with treatment.6
Amphotericin B has been a standby treatment during this developing crisisw5; the drug can be used in short courses and gives >90% cure rate.7 In addition, the aminoglycoside paromomycin, effective in phase II trials,8 is likely to be approved after a pivotal phase III study is completed. However, it is the alkylphosphocholine miltefosine (fig 3), first developed as an anticancer drug and which can be taken orally, that offers the most hope. In a series of trials this drug achieved a 94% cure rate at doses of about 2.5 mg/kg (100 mg/day for four weeks) even among patients with antimony resistant disease.9w6 Miltefosine was registered for treating visceral leishmaniasis in India in March 2002. Subsequent trials in children have returned similar results. Because of its teratogenic potential, this drug should be used with caution in women of childbearing age. Another potential oral drug sitamaquine, an aminoquinoline, lacked a linear correlation between dose and cure rates and had an unsatisfactory safety and efficacy profile.w7
HIV co-infections with L infantum and occasionally cutaneous leishmaniasis have proved difficult to treat, with over 60% failure rate after treatment with most antileishmanial drugs used either alone or in combination.w8 HAART (highly active antiretroviral therapy) has some effect on the relapse rate.10
Over 90% of cases of cutaneous leishmaniasis (irrespective of the parasite species responsible) heal spontaneously within 3-18 months, and the rationale for drug use and determination of drug efficacy are different from those for visceral leishmaniasis. A three week course of antimonial drug is the most common treatment, especially in patients with disfiguring or relapsing cutaneous or mucocutaneous leishmaniasis.w9
Trials with paromomycin ointments indicate considerable potential for treating cutaneous leishmaniasis (box 2). Imiquimod, an immunomodulator for genital warts, produced 90% cure rate when the ointment was used in conjunction with antimonials in 12 patients with cutaneous leishmaniasis in Peru who had not responded to antimony alone.11 The potential of this approach is yet to be fully exploited.
Oral drugs have also shown promise. In an open label study in Colombia four weeks' treatment with miltefosine, 133 mg and 150 mg daily cured 100% and 89% of patients respectively.12 For 20 years there has been interest in antifungal azoles for treating leishmaniasis, based on both microbial organisms having ergosterol as their predominant sterol. Most trials have been limited, and results are equivocal. Indications from controlled clinical trials are that ketoconazole has some potential against L mexicana infection,w13 and recently fluconazole 200 mg/day for six weeks led to healing of cutaneous leishmaniasis (L major) in 79% of patients compared with 34% with placebo.13
Box 3: Current research priorities for treating leishmaniasis
Develop easy drug sensitivity assays
Test oral miltefosine in regions other than Indian subcontinent for visceral and cutaneous leishmaniasis and variants
Complete registration requirement of paromomycin in India, initiate trials in South America and other regions
Investigate oral sitamaquine in Africa and Indian subcontinent
Develop cheaper indigenous formulations of lipid amphotericin
Test multiple drug treatment to protect current and future drugs.
Box 4: Current research priorities for vector and reservoir control
Develop rapid and accurate diagnostic test for dogs infected with zoonotic visceral leishmaniasis
Measure impact of community-wide use of insecticide treated dog collars on the incidence of zoonotic visceral leishmaniasis in children in different settings
Measure impact of using insecticide treated bed nets on leishmaniasis in different settings, including the relative impacts of household protection versus the mass effect
Test effectiveness of new applications of insecticide—such as cattle sponging against visceral leishmaniasis in Indian subcontinent, insect repellent lamps in regions with high rates of indoor biting at dusk by sandfly vectors, insecticide treated bed sheets and clothing or plastic sheeting for refugee camps
Develop high resolution maps of leishmaniasis risk and amenability to particular control activities in order to help rationalise the targeting of interventions
Vector and reservoir control
Insecticide spraying of houses
Spraying houses with insecticide is the most widely used intervention for controlling sandflies that are endophilic (rest mostly indoors after feeding). House spraying with the pyrethroid lambdacyhalothrin reduced the odds of cutaneous leishmaniasis in Kabul by 60%14 and reduced the risk of cutaneous leishmaniasis in the Peruvian Andes by 54%.15 Both trials measured protection at the household level, and it remains unclear under what circumstances “blanket spraying” of all houses in a village would have an additional mass effect on sandfly populations.w14 Such evaluations are crucial for the cost effective targeting of house spraying. For example, in Sao Paulo State (Brazil) spraying against sandflies is activated by the reporting in a municipality of more than two cases of cutaneous leishmaniasis in a single year.w15 Sustainability is vital, as cessation of spraying campaigns invariably leads to the re-emergence of leishmaniasis to pre-control levels.w16
Where sandflies are endophagic (mainly feed indoors) and most active when people are asleep, bed nets provide considerable protection. For example, a case-control study in Nepal showed that people using untreated nets were 70% less likely to develop visceral leishmaniasis than people without nets.16 Protection provided by wide mesh nets is enhanced by treating them with pyrethroids—reducing sandfly biting rates by 64%-100%.w17 w18 There is also evidence from Colombia that sandfly bites are not diverted to people sleeping outside insecticide treated nets: “unprotected” people in the same room as someone sleeping under a deltamethrin treated net received 42% less sandfly bites than people in houses without nets.w17 After encouraging, but inconclusive, results from small scale epidemiological trials in Iran,w19 Syria,17 and Sudan (D El Naiem personal communication), the household trial in Kabul showed that permethrin treated nets were no less effective than house spraying, reducing cutaneous leishmaniasis risk by 65%.
This result cannot be extrapolated elsewhere, as effectiveness of insecticide treated bed nets is determined by local sandfly behaviour. It is unclear, for example, whether the provision of about 300 000 such nets by Médecins Sans Frontières in eastern Sudan during 1998-2001 substantially reduced the incidence of visceral leishmaniasis (R Davidson personal communication). To our knowledge, insecticide treated nets have not been introduced outside the Sudan by any leishmaniasis control programme (as opposed to a trial) except in Afghanistan and Pakistan, where they have been provided by HealthNet to patients with active cutaneous lesions (L tropica). Their aim is not to protect the patients but to block transmission, as L tropica is transmitted anthroponotically. As with house spraying, it is unclear whether the widespread use of insecticide treated nets will have any mass effect, as there was no detectable impact on sandfly abundance in either the Iranian or Syrian trial.17w19 However, a recent cluster randomised trial in Venezuela showed that village-wide treatment of loosely hanging curtains with lambdacyhalothrin significantly reduced indoor sandfly abundance and eliminated cutaneous leishmaniasis risk.w20
Box 5: New targets for vaccination—sandfly saliva
Sandfly saliva contains a variety of immunogenic proteins, including some that enhance parasite survival by inhibiting macrophage functionw28
Vaccine induced immunity to saliva stimulates a vigorous delayed type hypersensitivity response after a bite, generating conditions unfavourable for parasite survivalw29
The effectiveness of this approach in humans remains to be tested
Epidemiological studies should determine whether natural immunity to saliva dictates patterns of infection
Control of zoonotic infection
In Brazil about 200 000 houses are sprayed and 20 000 dogs are culled each year to prevent zoonotic visceral leishmaniasis. After annual surveys in endemic regions, dogs are culled if their blood samples are diagnosed positive by immunofluorescence. Although experimental trials indicate that dog control may reduce Leishmania incidence in both dogs and children,18 concerns over the delays between sampling, diagnosis, and culling, and a failure to reduce the number of notified cases, have led to scepticism of the effectiveness of the Brazilian control programme.w21 More effective diagnostic tools may allow culling without delay,w22 but a recent trial of the rK39 dipstick test (see above) showed poor specificity (<75%) for diagnosing infected dogs.19
Box 6: Current research priorities for vaccine control
Develop a coordinated approach to evaluating vaccine candidate antigens, minimising duplication of effort and maximising use of limited financial resources
Immunogenicity testing of candidate vaccine antigens in humans, adopting a broad-based analysis of both CD4 and CD8 T cell function
Further analyse the immune response during “leishmanisation,” which offers the first real prospect of understanding the ontogeny of the human immune response
Develop new challenge models for visceral leishmaniasis, mimicking sandfly infection
Evaluate vaccines for canine visceral leishmaniasis, for veterinary use and as aids to controlling human disease
In the absence of a reliable and rapid tool for detecting infected dogs, alternative control strategies for zoonotic visceral leishmaniasis are being sought. Dipping dogs in insecticidew23 or applying topical insecticide lotions20 can substantially reduce sandfly bites on dogs and so protect them from infection, but this strategy requires regular retreatment as the insecticidal effect is short lived. However, a novel method for topical application of insecticide on dogs enables the insecticidal effect to persist for up to eight months.w24 Experimental trials have consistently shown that deltamethrin treated collars (fig 4) reduce by up to 90% the proportion of sandflies that take a blood meal and survive.20w24 Widespread use of these collars with domestic dogs in Italy reduced their risk of being infected by L infantum,w25 and a matched cluster randomised trial in Iran showed that, not only was the odds of infection in dogs reduced by 54%, but children living in the treated villages had significantly less risk of infection as well (odds ratio 0.57).21
Progress in vaccine development
Of all the parasitic diseases, leishmaniasis is considered the most likely to succumb to vaccination. The parasite has a particularly simple life cycle (fig 5), resolution of primary cutaneous leishmaniasis usually results in resistance to re-infection, and studies in experimental models have suggested simple CD4 Th1-type, cell mediated resistance (involving activation of macrophage killing mechanisms by T lymphocyte-derived interferon γ). In experimental models of cutaneous leishmaniasis, in which CD4 Th1 responses are driven towards a polarised Th1 response, protection can indeed be achieved by vaccination, although this rarely results in complete protection from development of lesions. Such vaccines, however, stimulate only poor memory, and protection wanes after a few weeks.22 In primate studies and clinical trials they show immunogenicity but rarely give appreciable protection. 23 24w26
TDR. Leishmaniasis. www.who.int/tdr/diseases/leish (accessed 13 Dec 2002)
Communicable Disease Surveillance and Response (CSR). Leishmaniasis. www.who.int/emc/diseases/leish (accessed 13 Dec 2002)
World Health Organization. Leishmaniasis (kala azar). www.who.int/health-topics/leishmaniasis.htm (accessed 13 Dec 2002)
CDC Division of Parasitic Diseases. Leishmania infection (leishmaniasis). www.cdc.gov/ncidod/dpd/parasites/leishmania (accessed 13 Dec 2002)—Also a useful educational resource for patients
Wellcome Trust. Leishmaniasis (Topics in International Health) [CD Rom]. Wallingford: CABI Publishing, 2000.
World Health Organization. Manual on visceral leishmaniasis control. Geneva: Division of Control of Tropical Diseases, 1996. (WHO/LEISH/96.40.)
Osman OF, Kager PA, Oskam L. Leishmaniasis in the Sudan: a literature review with emphasis on clinical aspects. Trop Med Int Health 2000;5:553-62
Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001;6:849-54
Croft SL. Monitoring drug resistance in leishmaniasis. Trop Med Int Health 2001;6:899-905.
Moore E, O'Flaherty D, Heuvelmans H, Seaman J, Veeken H, de Wit S, et al. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull WHO 2001;79:388-93
Schallig HD, Oskam L. Review: molecular biological applications in the diagnosis and control of leishmaniasis and parasite identification. Trop Med Int Health 2002;7:641-51
Guerin PJ, Olliaro P, Sundar S, Boelart M, Croft SL, Desjeux P, et al. Visceral leishmaniasis: current status of control, diagnosis and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002;2:494-501
In the past three to four years our view of the requirements for vaccine induced immunity has changed. A major paradigm shift reflects the role of CD8 T cells. New models of cutaneous leishmaniasis indicate that CD8 cells are vital for primary resistance.24 It has also been recognised that CD8 cells are required for the maintenance of long term vaccine induced immunity. Although the capacity to induce CD8 cell responses is a feature of DNA vaccines, this has also been shown for some protein based vaccines.25
Although clinical trials continue with crude autoclaved L major, some defined protein antigens have been identified, sometimes rationally, sometimes by serendipity.22 The Leishmania Genome Project (www.sanger.ac.uk/Projects/L_major/) provides an impetus for immunisation with an expression library of the parasite to screen all expressed proteins.26 Recent advances in combining vaccine delivery systems in so called prime-boost schedules are also being tested in models of cutaneous leishmaniasis.w27 The bottleneck imposed by producing materials to the standards of good laboratory practice (GLP) and good manufacturing practice (GMP) and the costs of trials are major hurdles in taking any of these discoveries further. A $15m (£9.4m; €15.1m) award from the Bill and Melinda Gates Foundation to support vaccine development at the Infectious Disease Research Institute in Seattle is a welcome boost. A recombinant vaccine (Trifusion, a fusion peptide of the leishmanial antigens LMST11, TSA, and LeIF) is being prepared for clinical trials, and the recent observation that Trifusion, given in combination with immunostimulatory CpG oligodeoxynucleotides, stimulated CD4 and CD8 cells and long term immunity is encouraging.25
Rapid progress in vaccine development is also hindered when natural challenge is the only means of validation. In this regard, the resurrection of “leishmanisation” sponsored by the World Health Organization and the Special Programme for Research and Training in Tropical Diseases (TDR) is a major step forward. Leishmanisation (active infection to produce natural resistance) was once common in the Middle East and eastern Europe to minimise the impact of scarring but was largely discontinued because of unacceptable lesions in some recipients. However, scientists in Iran have now produced L major stabilates (populations stored in a genetically stable and viable condition) to GLP standard, which should produce consistent and acceptable lesions. Leishmanisation may thus provide an ethically acceptable means of live vaccine challenge in endemic areas.
For visceral leishmaniasis, the situation remains less promising, and, although there are concerns about whether the same vaccine will work for all leishmaniases, human trials of vaccines against visceral leishmaniasis are likely to follow only from successful outcomes of those against cutaneous leishmaniasis, or as in the Sudan, on a compassionate basis.27 Recent reports suggest some progress is being made in vaccines for canine visceral leishmaniasis.28w30
Competing interests CRD has been reimbursed by InterVet, manufacturer of Scalibor, for attending conferences. SLC was paid by Zentaris, manufacturer of miltefosine, for writing part of the dossier for drug registration.
References w1-w30 are listed on bmj.com